@PFDesktop\::ODMA/MHODMA/HBSR05;iManage;646401;1 DES/CMW/atc September 15, 2006

PATENT APPLICATION DOCKET NO.: 3518.1015-000

HE UNITED STATES PATENT AND TRADÈMARK OFFICE

Applicant SEP 2 1 2006 Thomas M. DiMauro, Mohamed Attawia, Hassan Serhan, Martin A. Reynolds, Melissa Grace, Sudhakar Kadiyala, David Urbahns, Scott Bruder, Gregory Collins, Laura J. Brown, Jeff Greesin, Pamela L. Plouhar, Catherine Smith and John Siekierka

Application No.:

10/630,227

Group Art Unit:

1647

Filed:

July 30, 2003

Examiner:

Shulamith H. Shafer

Confirmation No.:

8291

Title:

TRANS-CAPSULAR ADMINISTRATION OF HIGH SPECIFICITY CYTOKINE INHIBITORS INTO ORTHOPEDIC JOINTS

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patern and Trademark Office on:

Date

nature

Amy T. Comeau

Typed or printed name of person signing certificate

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:			
This I	nformation Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)		
[]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date o stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional CPA, or a Request for Continued Examination).		
[X]	under 37 CFR 1.97(c) together with either: [] a Statement under 37 CFR 1.97(e), as checked below, or	K30227	180.00
	[X] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)	00000005 10630227	
[]	under 37 CFR 1.97(d) together with: [] a Statement under 37 CFR 1.97(e), as checked below, and	_	
	[] a \$180.00 fee under 37 CFR 1.17(p), or	26 ТТВАН1	*

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

[]	Appl	under 37 CFR 1.97(i): Applicant requests that the IDS and cited reference(s) be placed in the application file. (Filed after payment of issue fee)			
State	ement Ur	der 37 (CFR 1.97(e)		
[]	any co	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or			
[]	comm know in the	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.			
State	ement Ur	nder 37	(Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000		
[]	comn was n	nunication of recei	information contained in the Information Disclosure Statement was cited in a in from a foreign patent office in a counterpart application and this communication red by any individual designated in § 1.56(c) more than thirty days prior to the information Disclosure Statement.		
[X]	Enclosed herewith is form PTO-1449:				
	[X]	Copie	s of the cited references [B21-B23, C116-C122] are enclosed.		
		[X]	Copies of issued U.S. patents and published U.S. applications are not required an are not being provided.		
	[]	Appli	s of the cited references are enclosed except those entered in prior application, U.S ration No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier ation contains copies of the cited references.]		
	[X]	The li Searc	sted references [B21-B22, C116-C120] were cited in the enclosed International Report in a counterpart foreign application.		
	[]	The "- 37 CF	oncise explanation" requirement (non-English references) for references [-] under R 1.98(a)(3) is satisfied by:		
		[]	the explanation provided on the attached sheet.		
		[]	the explanation provided in the Specification.		
		[]	submission of the enclosed International Search Report.		
		[]	submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.		
		[]	the enclosed English language abstract.		

[]			ant requests that the following n		
Examiner's Initials					
 			U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
			U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
			U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
			Examiner	Date	-
	[]	A copy of each above-cited app any application filed on or after Image File Wrapper (IFW) syst	June 30, 2003, which has be	een scanned into the PTO's
	[]	A copy of each above-cited app those entered in prior application 35 U.S.C. 120 is claimed.	olication, including the current on, U.S. Application No. [nt claims, is enclosed, except], to which priority under
The Ex	xan	niner s wei	is requested to return a copy of re considered with the next offic	the above list of pending appe communication.	olications indicating which
It is re	que	ested	that the information disclosed h	erein be made of record in the	nis application.
Metho	d o	f pay	yment:		
[X]			ck for the fee noted above is enclosed panying Reply. A copy of this S		luded in the check with the
[]	Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.				
[X]	Pl	ease	charge any deficiency in fees an	nd credit any overpayment to	Deposit Account 08-0380.
•			F	Respectfully submitted,	
			F	HAMILTON, BROOK, SMI	ΓΗ & REYNOLDS, P.C.
			F	Deirdre E. Sanders Registration No.: 42,122 Telephone: (978) 341-0036 Facsimile: (978) 341-0136	alex

Concord, MA 01742-9133 Dated: September 18,200 &

			Sheet 1 of
PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. APPLICATION NO. 10/630,227		
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Thomas M. DiMauro FILING DATE July 30, 2003)3
SEP 2 1 2006 Use several sheets if necessary)	EXAMINER Shulamith H. Shafer	CONFIRMATION NO. 8291	GROUP 1647

TRADEMINE		U.S. PATENT DOCUMENTS		
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	A45	2002/0082697 A1	06-27-2002	Damien
	A46	2004/0022864 A1	02-05-2004	Freyman et al.
	A47	2004/0126372 A1	07-01-2004	Banerjee et al.

FOREIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSI YES	LATION NO
B21	WO 2005/110276 A1	11-24-2005	Massachusetts General Hospital		
B22	WO 2005/000283 A2	01-06-2005	DePuy Spine, Inc.		
B23	WO 2006/031376 A2	03-23-2006	DePuy Spine, Inc.		

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
	C116	Hawks, D., "Alternative Medicine: Musculoskeletal System," Clin. Tech. Small Anim. Pract., 17(1):41-49 (2002).			
•	C117	Khot, A. et al., "The Use of Intradiscal Steroid Therapy for Lumbar Spinal Discogenic Pain - A Randomized Controlled Trial," Spine, 29(8):833-837 (2004).			
	C118	Földes, I. et al., "Trace Elements in Tissues of Normal and Vitamin D ₂ -Treated Rats," ACTA Biol. Acad. Sci. Hung., 26(3-4):141-150 (1975).			
	C119	CN 1 647 808 A (Zhou C) 2005-08-03 (abstract) World Patents Index [online]. London, GB: Derwent Publications, Ltd., Week 200621, Class B04, Accession No. 2006-194507.			
:	C120	CN 1 569 039 A (Niu X) 2005-01-26 (abstract) World Patents Index [online]. London, GB: Derwent Publications, Ltd., Week 200577, Class B04, Accession No. 2005-749289.			
	C121	Tracey, K.J. and Cerami, A., "Tumor Necrosis Factor in Metabolism of Disease: Hormonal Actions Versus Local Tissue Effects," <i>Nouv. Rev. Fr. Hematol.</i> , 34 Suppl:S37-42 (1992) (abstract).			
	C122	Crevensten, G. et al., "Intervertebral Disc Cell Therapy for Regeneration: Mesenchymal Stem Cell Implantation in Rat Intervertebral Discs," Ann. Biomed. Eng., 32(3):430-434 (2004).			

EXAMINER	DATE CONSIDERED